BARD1 Gene Mutations
Information about Inherited BARD1 Mutations
What is BARD1?
BARD1 is a gene that helps repair damage to your DNA. People who are born with changes—called mutations—in their BARD1 gene have an increased risk for cancer.
What are the cancer risks for people with a BARD1 mutation?
Mutations in the BARD1 gene have been linked to increased risk for breast cancer in women. Currently, it is not believed that BARD1 mutations increase the risk for other cancers, but research on this is continuing.
What can people with a BARD1 mutation do?
There are guidelines based on the latest research for breast cancer risk management in women with a BARD1 mutation.
People with a BARD1 mutation who have been diagnosed with some types of cancer may qualify for specific treatments or clinical trials using targeted therapies.
If you test positive for a BARD1 mutation, you should inform your close blood relatives (first-, second-, and third-degree relatives) about your test results and encourage them to speak with a genetics expert.
Each of these topics is outlined in more detail in the sections highlighted below.
Want to stay informed about related content?
Get notified when updated information becomes available.
SIGN UP FOR CONTENT UPDATES
More Information for people with BARD1 Mutations
Cancer Risks
Cancer risk estimates are updated based on the latest research. Read about the lifetime risk for cancer in people with inherited BARD1 mutations.
Risk Management Options
Read about the latest expert guidelines for cancer screening and prevention for people with a BARD1 mutation.
Cancer Treatment Options
People who test positive for a BARD1 mutation may have additional treatment or clinical trial options available to them.
Participate in Treatment Research
The treatment studies below are enrolling people with mutations. To search for more studies, visit our Search and Enroll Tool.
Clinicaltrials.gov identifier: NCT04038502
New Treatment in People with Triple Negative Breast Cancer or Advanced Solid Tumors
Clinicaltrials.gov identifier: NCT06022029
